Abstract Details

Title Comparison of Clinical Disease Expression of Multiple Sclerosis between Hispanics and Non-Hispanics

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 127

Objective

Background BACKGROUND: The clinical expression of MS is not well characterized in South Floridian Hispanics from mostly Caribbean ancestry.

Design/Methods DESIGN/METHODS: HW (n=290) and NHW (n=279) MS cases were ascertained through our MS clinic and through patient outreach efforts that serve the Miami area. A detailed race/ethnicity history was established spanning three generations. Clinical disease characteristics were obtained through a review of the medical records of participants.

Results RESULTS: We observed a significant difference in diagnostic lag (time between the first symptom and diagnosis) between HW and NHW, attributed to differences in the source of ascertainment between the two groups. Age at onset was marginally significant (P-value = 0.07), while the symptoms at onset did not significantly differ in the two groups. However, HW patients presented with a significantly lower frequency of motor weakness (P-value = 0.01), ataxia (P-value = 0.02), and bladder disturbance (P-value = 0.004) during the course of illness than NHW. Optic neuritis as the presenting symptom of MS was low in both groups (HW = 16% NHW 17%). Disease progression as measured by the EDSS was not significantly associated with race/ethnicity. Lastly, HW were observed to respond to IFN-beta more favorably than NHW, an association which persists after adjusting for the source of ascertainment (P-value = 0.02).

Conclusions CONCLUSIONS: HW living in South Florida are less likely to experience symptoms of motor weakness, ataxia and bladder disturbance than NHW. Interferon-beta treatment is more effective in HW compared to NHW. The HW in our center, mostly Caribbean, differ from previously described characterizations of Hispanics of mostly Mexican ancestry. This further solidifys that Hispanics are not a homogenous group and additional study is warranted.

Authors/Disclosures
Sylvia R. Delgado, MD, FAAN (University of Miami School of Medicine) PRESENTER	The institution of Dr. Delgado has received research support from Novartis. The institution of Dr. Delgado has received research support from EMD Serono.
	No disclosure on file
	No disclosure on file
Melissa R. Ortega, MD (University of Miami)	An immediate family member of Dr. Ortega has received personal compensation for serving as an employee of Aptitude. An immediate family member of Dr. Ortega has received personal compensation for serving as an employee of Oncocyte. An immediate family member of Dr. Ortega has received personal compensation for serving as an employee of Total Health Information.
Ashley Beecham	The institution of Ashley Beecham has received research support from National Multiple Sclerosis Society.
Edward Fox, MD, PhD, FAAN	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Fox has received research support from Biogen. The institution of Dr. Fox has received research support from Genentech. The institution of Dr. Fox has received research support from Celgene - BMS. The institution of Dr. Fox has received research support from Chugai. The institution of Dr. Fox has received research support from Novartis. The institution of Dr. Fox has received research support from EMD-Serono. The institution of Dr. Fox has received research support from TG Therapeutics. The institution of Dr. Fox has received research support from AbbVie. The institution of Dr. Fox has received research support from Sanofi Genzyme. The institution of Dr. Fox has received research support from AbbVie.
Leticia Tornes, MD, FAAN (University of Miami)	Dr. Tornes has nothing to disclose.
Margaret A. Pericak-Vance, PhD (University of Miami Miller School of Medicine)	Dr. Pericak-Vance has nothing to disclose.
Kottil W. Rammohan, MD (University of Miami)	Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Rammohan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Rammohan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. The institution of Dr. Rammohan has received research support from Genentech. The institution of Dr. Rammohan has received research support from Genzyme. The institution of Dr. Rammohan has received research support from EMD Serono. The institution of Dr. Rammohan has received research support from Alexion.
Jacob L. McCauley (University of Miami)	No disclosure on file

��ɫ��

��ɫ��